Work

Abstract 4135443: A Phase 1, Single Ascending Dose Study to Evaluate ALN-TTRsc04, a Next-Generation RNA Interference Therapeutic, in Healthy Participants for Potential Treatment of Transthyretin Amyloidosis

Year: 2024

Type: conference-abstract

Source: Circulation

DOI: 10.1161/circ.150.suppl_1.4135443

Authors: Ali Murad, Maxwell Lasko, Prajakta Badri, Satyawan Jadhav, Katherine Boyle, Juanjuan Li, John Vest, Jorg Taubel

Institutions: Alnylam Pharmaceuticals (United States), St George's, University of London

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404302575

Cites:

Cited by: 2

Related to: 10